We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of imipenem and ceftazidime as therapy for severe melioidosis.
- Authors
Simpson, A J; Suputtamongkol, Y; Smith, M D; Angus, B J; Rajanuwong, A; Wuthiekanun, V; Howe, P A; Walsh, A L; Chaowagul, W; White, N J
- Abstract
An open, prospective, randomized, comparative treatment trial was conducted to compare the therapeutic efficacy of high-dose intravenous imipenem and ceftazidime for acute severe melioidosis. Adult Thai patients with suspected acute, severe melioidosis were randomized to receive either imipenem, at a dosage of 50 mg/(kg x d), or ceftazidime, at a dosage of 120 mg/(kg x d), for a minimum of 10 days. The main outcome measures were death or treatment failure. Of the 296 patients enrolled, 214 had culture-confirmed melioidosis, and 132 (61.7%) of them had positive blood cultures. Mortality among patients with melioidosis was 36.9% overall. There were no differences in survival overall (P = .96) or after 48 hours (P = .3). Treatment failure after 48 hours was more common among patients treated with ceftazidime (P = .011). Both treatments were well tolerated. Imipenem is a safe and effective treatment for acute severe melioidosis and may be considered an alternative to ceftazidime.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Vol 29, Issue 2, p381
- ISSN
1058-4838
- Publication type
Journal Article
- DOI
10.1086/520219